Pharma major Ind-Swift Laboratories Ltd. has obtained the US FDA nod for its five Active Pharmaceutical Ingredients or APIs manufactured at its Derabassi manufacturing facility.
The products for which the company has obtained the approval are Naratriptan Hydrochloride (anti-migraine), Ropinirole Hydrochloride (anti-Parkinson's disease), Donepezil Hydrochloride (anti-Alzheimer's disease), Acamprosate Calcium (anti-alcohol dependence) and Clarithromycin (Macrolide antibiotic).
With this approval, the company will be able to sell its products in the US market. The worldwide market for these products is $5 billion.
The company's Derabassi facility is already accredited by key accreditation agencies such as TGA, MHRA, COS, KFDA and PMDA.
Commenting on the development, Vice Chairman and Managing Director N.R. Munjal said, "This multi product approval will give multifold aggression to the sales as we have good presence in US through our US subsidiary and we expect this approval to give additional 50 percent to 60 percent growth in US sales."
At the BSE, Ind-Swift Laboratories closed Tuesday's trading at Rs.98.65, up 3.30 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.